ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

OPK Opko Health Inc

1.28
-0.02 (-1.54%)
Pre Mercado
Última actualización: 06:29:02
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Opko Health Inc OPK NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.02 -1.54% 1.28 06:29:02
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.30
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/5/202407:00GLOBEOPKO Health to Report First Quarter 2024 Financial Results..
28/3/202407:00PRNUSLabcorp Announces Acquisition of Select Assets of..
20/3/202407:00GLOBEEntera Bio Announces Robust Pharmacokinetic Data for..
07/3/202415:02EDGAR2Form ARS - Annual Report to Security Holders
05/3/202407:52GLOBEAIDS Clinical Trial Group Presents Results from Phase 1..
01/3/202415:05EDGAR2Form NT 10-K - Notification of inability to timely file Form..
28/2/202408:31PRNUSNextPlat Opens OPKO Health-Branded Storefront on Alibaba's..
27/2/202415:07EDGAR2Form 8-K - Current report
27/2/202415:05GLOBEOPKO Health Reports Fourth Quarter 2023 Business Highlights..
22/2/202415:05GLOBEOPKO Health to Report Fourth Quarter 2023 Financial Results..
16/2/202415:53EDGAR2Form PRE 14A - Other preliminary proxy statements
09/2/202415:07EDGAR2Form 8-K - Current report
05/2/202407:09PRNUSNextPlat Receives Initial Approvals to Launch OPKO..
29/1/202414:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202415:15EDGAR2Form SC 13D/A - General statement of acquisition of..
24/1/202415:00EDGAR2Form 8-K - Current report
17/1/202416:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202416:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202416:09EDGAR2Form 8-K - Current report
09/1/202415:05GLOBEOPKO Health Announces Closing of Private Offering of $230..
08/1/202408:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202407:00GLOBEOPKO Health to Present at the 42nd Annual J.P. Morgan..
05/1/202416:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202412:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202411:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202406:00EDGAR2Form 8-K - Current report
04/1/202422:31GLOBEOPKO Health Announces Pricing of Private Offering of $200..
03/1/202416:05GLOBEOPKO Health Announces Private Offering of Convertible Senior..
28/11/202306:00PRNUSBioReference Health and Prognos Health Collaborate to..
13/11/202307:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202307:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202305:45PRNUSBioReference® Signs On as the First Laboratory to Use..
06/11/202315:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:06EDGAR2Form 8-K - Current report
06/11/202315:05GLOBEOPKO Health Reports Third Quarter 2023 Business Highlights..
02/11/202309:00GLOBENew Clinical Data on OPKO Health’s RAYALDEE® (ER..
31/10/202315:08EDGAR2Form 8-K/A - Current report: [Amend]
31/10/202307:00GLOBEOPKO Health to Report Third Quarter 2023 Financial Results..
25/10/202315:25GLOBEOPKO Health to Present New Clinical Data on Rayaldee (ER..
28/9/202316:10DJNModeX Therapeutics Awarded Contract to Address Public Health..
28/9/202315:09EDGAR2Form 8-K - Current report
28/9/202315:08GLOBEModeX Therapeutics Secures BARDA Contract to Develop Novel..
12/9/202307:30GLOBEEntera Bio Announces Collaboration with OPKO Biologics to..
03/8/202315:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202315:07EDGAR2Form 8-K - Current report
03/8/202315:05GLOBEOPKO Health Reports Second Quarter 2023 Business Highlights..
25/7/202315:05GLOBEOPKO Health to Report Second Quarter 2023 Financial Results..
30/6/202315:10EDGAR2Form 8-K - Current report
28/6/202305:45BWFDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly..

Su Consulta Reciente

Delayed Upgrade Clock